Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
panitumumab-IRDye800CW
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**panitumumab-IRDye800CW** is an investigational, systemically administered near-infrared fluorescence imaging agent consisting of the fully human anti-EGFR monoclonal antibody panitumumab covalently conjugated to IRDye800CW. It binds epidermal growth factor receptor on EGFR-expressing tumor cells and enables fluorescence-guided visualization of tumors, surgical margins, metastatic lymph nodes, and residual disease during surgery. It is being evaluated as an optical diagnostic agent in head and neck squamous cell carcinoma, pancreatic cancer, lung cancer, malignant glioma, and pediatric brain tumors; it is not an approved therapeutic formulation of panitumumab. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4241857/))
- Other names
- PAN800PAN-800PAN 800panitumumab-IRDye800panitumumab-IRDye-800panitumumab-IRDye 800panitumumab-IRDye800CWpanitumumab-IRDye-800CWpanitumumab-IRDye 800CW
02
Targets
Beyond the preview
Go deeper on panitumumab-IRDye800CW.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on panitumumab-IRDye800CW.